Welcome to UroGen®
UroGen has a steadfast commitment to elevating options for people living with urological cancers. With breakthrough technology we are able to break barriers to treatment, pioneering a future of new possibilities in transformative therapies.
Innovation that
champions patients
Possibilities
brought to life
Our story
is dynamic
Explore UroGen news
Oct 15, 2024
UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
about UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
Oct 9, 2024
UroGen Appoints Chris Degnan as Chief Financial Officer
about UroGen Appoints Chris Degnan as Chief Financial Officer
Oct 2, 2024
First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
about First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Sep 16, 2024
UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041
about UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041
Sep 5, 2024
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
about UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 29, 2024
UroGen Pharma to Present at Upcoming Investor Conferences
about UroGen Pharma to Present at Upcoming Investor Conferences
Aug 14, 2024
UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
about UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Aug 13, 2024
UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights
about UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights
Aug 5, 2024
UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
about UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
Jun 17, 2024
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
about UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants